Santos Dumont and the Demoiselle: When Sharing an Invention Becomes an Innovation Strategy
News

Santos Dumont and the Demoiselle: When Sharing an Invention Becomes an Innovation Strategy

When aviation was still in its early stages, Alberto Santos Dumont took an unusual approach to technological innovation. Rather than restricting access to one of his aircraft designs, he made the construction plans for the Demoiselle publicly available.

Developed between 1907 and 1909, the aircraft was compact, lightweight, and relatively straightforward to build by the standards of its time. In 1910, detailed drawings were published in Popular Mechanics, allowing interested readers to study the specifications and reproduce the design.

The initiative helped spread aeronautical knowledge and enabled different manufacturers to build the aircraft. It also offers a historical perspective on a question that remains relevant to companies, researchers, and inventors: how can innovation be protected while knowledge is made more widely available?

The Demoiselle: an innovation open to reproduction

The Demoiselle, also known as La Demoiselle, was one of Santos Dumont’s last aircraft. Its first model flew in 1907, and subsequent versions improved through 1909.

The aircraft stood out for its small dimensions and lightweight structure. Its design evolved through several versions, reflecting the experimentation and technical refinement that characterized aeronautical development at the time.

In 1910, Santos Dumont made detailed plans for the aircraft publicly available. This gave others access to the technical information needed to build their own units, without relying exclusively on the inventor.

According to records from the Brazilian Air Force’s Aerospace Museum, some factories began producing the Demoiselle in 1909, and they built more than 40 units. The aircraft is often cited as one of the earliest examples of a mass-produced airplane.

Santos Dumont’s decision to share the design reflected his belief that his inventions should contribute to aviation’s development and benefit society.

Knowledge sharing and technological development

The Demoiselle’s history illustrates how access to technical information can help spread a technology.

By making the drawings available, Santos Dumont allowed other builders to study his solutions, adapt the design, and explore its potential. The initiative helped reduce an important barrier to reproducing the aircraft: access to the knowledge required to build it.

This approach has parallels with modern open innovation practices, in which companies, universities and researchers share knowledge, technologies or resources to accelerate the development of new solutions.

Today, such collaboration can take place through scientific publications, open licenses, collaborative projects, technology transfer and research partnerships.

Although the mechanisms differ, the underlying principle is similar: letting knowledge circulate can expand opportunities for experimentation and enable others to build new solutions on existing technologies.

Patents and innovation: protect or share?

Santos Dumont’s story also illustrates a strategic choice faced by inventors and companies: whether to protect an invention through intellectual property rights or make certain information available for broader use.

Patents can grant their owners a temporary exclusive right to an invention, provided they meet the applicable legal requirements. In return, the system requires the disclosure of technical information about the protected solution, contributing to the dissemination of technological knowledge.

A patent therefore does not mean that knowledge will remain permanently inaccessible. The patent system establishes conditions for protecting and disclosing inventions, as well as territorial and time limits on the rights granted.

Other approaches allow structured sharing of technologies, including licenses that authorize third parties to use an invention under agreed conditions.

Decisions about whether to protect, license, or openly share a technology should take several factors into account:

  • Commercial objectives: Does the company intend to commercialize the invention itself, license its use, or encourage wider market adoption?
  • Competitive advantage: Is exclusivity important for recovering research and development investments or establishing a market position?
  • Potential for dissemination: Could sharing encourage adoption, collaboration and the development of complementary solutions?
  • Business model: Does value depend on exclusive control of the technology or on services, complementary products, partnerships and network effects?

There is no single answer to these questions. The most appropriate strategy depends on the nature of the innovation, the resources invested, and the developer’s long-term objectives.

What can companies and researchers learn from the Demoiselle?

The Demoiselle shows that innovation management involves more than deciding whether to patent an invention. It also requires decisions about how knowledge will be made available, commercialized, and incorporated into new solutions.

For companies and research institutions, these considerations should form part of their intellectual property strategy from the early stages of technological development.

In some contexts, exclusivity may be essential to support investment and create licensing opportunities. In others, sharing can increase technology adoption, encourage partnerships and strengthen an innovation ecosystem.

It is also important to distinguish the disclosure of technical information from the grant of rights to use it. Publishing a design, making documentation available or sharing research findings does not, by itself, establish every legal condition governing third-party use. Those conditions depend on the rights involved and the applicable terms.

Santos Dumont’s historical experience does not provide a universal formula for intellectual property management, but it demonstrates how different choices can influence a technology’s development.

Innovation also depends on strategic choices

More than a century after the Demoiselle plans were published, the debate over protecting and sharing knowledge remains relevant in fields such as artificial intelligence, software, biotechnology and aerospace.

Companies developing new technologies need to consider not only how to protect their creations but also how to turn that knowledge into economic, scientific or social value.

Intellectual property provides tools for structuring these decisions. Its role extends beyond preventing copying: it can also support licensing, collaboration, technology transfer and different models of commercial exploitation.

The Demoiselle’s legacy reinforces the idea that innovation and sharing are not necessarily opposing goals. Understanding when to protect, when to license, and when to share is part of the strategy for turning knowledge into technological progress.

Semaglutide
News

Semaglutide Patent Expiry Opens a New Phase of Competition in Brazil’s Pharmaceutical Market

The expiry of the semaglutide patent in Brazil on March 20, 2026, opened the door to a new phase of competition in the market for medicines used to treat type 2 diabetes and manage weight. Months later, the effects are beginning to emerge, with new versions of the active ingredient entering the market and domestic and international pharmaceutical companies pursuing commercial opportunities.

According to a report published by EXAME on October 23, only two of the new synthetic versions identified in its survey were already available in Brazilian pharmacies: Ozivy, from EMS, and Semavy, from Hypera Pharma. Other companies were still awaiting regulatory or commercial steps before launching their products.

The developments illustrate how patent expiry can change competitive conditions without removing the other requirements involved in bringing a pharmaceutical product to market.

What changed when the patent expired?

In January 2026, Brazil’s Superior Court of Justice (STJ) Fourth Panel ruled against extending the patent terms for Ozempic and Rybelsus, both owned by Novo Nordisk. The decision followed the legal understanding that delays in administrative patent examination do not justify judicial extensions beyond the term established under Brazilian law.

The semaglutide patent subsequently expired on March 20, 2026, allowing other companies to develop medicines containing the same active ingredient, subject to the applicable regulatory requirements.

This marked a competitive turning point for Brazil’s pharmaceutical industry. Companies that had previously faced patent exclusivity as a barrier to entry gained new opportunities to develop and commercialize products.

However, patent expiry does not automatically authorize a medicine for manufacture and sale. Commercialization remains subject to health regulations, including demonstrating quality, safety, and efficacy to Brazilian Health Regulatory Agency (Anvisa).

Which companies are competing in this market?

The market’s opening has attracted manufacturers with different development, production, and distribution capabilities. Companies identified in EXAME’s report include EMS, Hypera Pharma, Ávita Care, Sun Pharmaceutical, Brainfarma, Ranbaxy and Germed.

Products are progressing through different regulatory and commercial stages. As of October 2026, Ozivy, from EMS, and Semavy, from Hypera Pharma, were the two new synthetic versions identified in the report as commercially available.

Other products, including Owozy, Seemasun, Zempneo, Orsema and Semaclique, had received regulatory approval but were not yet available in pharmacies, according to the report. The survey also identified a registration for a generic version of synthetic semaglutide from EMS.

The distinction between regulatory approval and commercial availability shows that entering a pharmaceutical market requires more than product development. Manufacturing capacity, distribution arrangements, commercial positioning, and compliance with applicable requirements can all affect launch timelines.

Why does patent expiry not end the intellectual property protection?

The expiry of a patent ends the exclusivity granted by that particular right, within the scope of its subject matter and term. It does not, by itself, mean that every technology associated with a medicine is free from intellectual property protection.

Depending on the circumstances, formulations, manufacturing processes, delivery devices and other technical solutions may be covered by separate rights, provided they meet the applicable legal requirements and are protected by valid titles.

Companies assessing market-entry opportunities must therefore consider the full set of potentially relevant rights rather than relying solely on the expiry date of the patent associated with an active ingredient.

In the pharmaceutical sector, this assessment can influence research and development decisions, licensing agreements, industrial partnerships and launch strategies. Identifying opportunities also requires careful examination of patent claims and the legal status of relevant rights.

Regulatory approval and commercial strategy are separate stages

The development of new semaglutide products also illustrates the difference between the ability to develop a product after patent exclusivity ends and the authorization to market it.

In March 2026, Anvisa reported that applications for medicines containing the same active ingredient were at different stages of review. The agency emphasized that patent expiry did not remove the requirement to demonstrate quality, safety, and efficacy.

The agency granted additional registrations in the following months. Nevertheless, regulatory approval did not mean that every product would immediately become available in pharmacies.

For pharmaceutical companies, this calls for integrated planning. Patent analysis must be considered alongside technological development, manufacturing capacity, regulatory processes, and commercial strategy.

It is also important to distinguish between a medicine’s approved indications. Authorization for one therapeutic purpose does not automatically permit marketing for another; the approved indications must be verified for each product.

What does this mean for the pharmaceutical industry?

The semaglutide case illustrates how changes in patent protection can reshape competition in a commercially significant market.

For manufacturers seeking to enter the sector, the end of exclusivity may create opportunities for product development and expansion. Companies already operating in the market may need to adjust their portfolios, differentiation, distribution, and competitive positioning.

The shift also highlights the importance of monitoring court decisions, patent terms and regulatory proceedings in a coordinated manner. An opportunity identified through intellectual property analysis must be assessed against the technical, legal and commercial conditions required to bring it to market.

Brazil’s semaglutide market therefore demonstrates that patent expiry is an important milestone, but not the end of strategic analysis. Assessing the protection landscape, understanding regulatory requirements, and planning market entry can be decisive for pharmaceutical companies competing in this segment.

Access rights in the digital world expand the debate on data, technology and innovation
News

Access rights in the digital world: implications for technology, data and intellectual property

The expansion of the digital economy is changing how companies access and use data, technological systems and digital platforms. As these resources become increasingly important to innovation and business development, access, interoperability and intellectual property are becoming closely connected.

For technology companies, understanding the conditions under which data, systems and digital assets can be accessed and used is increasingly relevant to product development, partnerships, licensing and intellectual property strategies.

Access and innovation in the digital economy

Access to data and technological resources can be essential for companies developing new products, services and digital solutions.

At the same time, access does not necessarily mean unrestricted use. Companies must consider issues involving data protection, contractual restrictions, security and the intellectual property rights associated with the technologies and information involved.

This creates an important balance between enabling access and protecting investments, rights and strategic assets.

Interoperability between systems

One of the central issues in the digital environment is interoperability — the ability of different systems, platforms and technologies to communicate and operate with one another.

For businesses, interoperability can facilitate:

  • integration between platforms and technological systems;
  • development of new products and services;
  • broader use of data and digital resources;
  • partnerships between technology providers;
  • innovation across different digital environments.

However, access to systems and technologies can also involve intellectual property considerations, particularly when companies rely on technologies, software or platforms developed and controlled by third parties.

Data, artificial intelligence and intellectual property

The growth of artificial intelligence adds another layer to the discussion.

AI systems can depend on large volumes of data for training, analysis and the development of new applications. This raises questions about who can access specific information, under which conditions, and for what purposes.

Companies developing AI-based technologies may therefore need to consider:

  • what data can be accessed and used;
  • what rights apply to that information;
  • whether contractual or legal restrictions exist;
  • how data can be shared with third parties;
  • how confidential information and intellectual property assets should be protected.

These considerations can influence both the development of new technologies and the way companies structure their innovation strategies.

Digital platforms and intellectual property

The discussion about access also has direct implications for intellectual property.

Software, databases, algorithms, digital content, trademarks and other technological assets may be subject to different forms of legal protection. Their use, integration and sharing therefore need to take into account the rights associated with those assets.

For companies operating in technology-intensive markets, these issues can affect decisions involving:

  • technology licensing;
  • partnerships and integrations;
  • access to third-party platforms;
  • information sharing;
  • protection of proprietary technologies;
  • management of intellectual property portfolios.

The challenge is to establish conditions that allow technologies and businesses to interact while preserving the rights and investments associated with digital assets.

Access and competition in digital markets

The way access to data, platforms and technological resources is structured can also affect competition.

When certain companies control essential digital infrastructure, data or technological resources, other businesses may face barriers when developing products or services that depend on them.

At the same time, access mechanisms need to consider the investments made by technology providers, intellectual property rights, information security, and the risk of unauthorized use.

This makes access an issue that goes beyond technology itself. It can also influence business models, innovation strategies and the management of intangible assets.

What technology companies should consider

As digital technologies become increasingly interconnected, companies may need to evaluate not only what they create, but also the technological and legal environment in which their products and assets operate.

For businesses developing or adopting new technologies, this may involve assessing:

  • ownership and protection of intellectual property assets;
  • rights associated with data and digital content;
  • licensing and technology-sharing arrangements;
  • interoperability requirements;
  • contractual restrictions on access and use;
  • protection of confidential and strategic information.

Understanding these aspects early can help companies structure their innovation and intellectual property strategies more effectively.

Intellectual property in the digital environment

The debate surrounding access rights demonstrates that digital innovation depends not only on the development of new technologies, but also on the rules governing how data, systems and digital assets can be accessed, used and connected.
For technology-driven companies, access, innovation and intellectual property are increasingly interconnected. Understanding this relationship can be relevant to decisions involving product development, partnerships, licensing and the protection of strategic assets.
Mercosur-EFTA trade agreement strengthens protection of intellectual property assets
News

Mercosur-EFTA trade agreement strengthens protection of intellectual property assets

Brazil has formalized the Mercosur-European Free Trade Association (EFTA) free trade agreement, covering Switzerland, Norway, Iceland and Liechtenstein. In addition to establishing new conditions for trade in goods and services, the agreement includes specific commitments concerning intellectual property (IP).

For Brazilian companies operating or planning to expand internationally, the IP provisions add a strategic consideration when entering and protecting assets in the European markets covered by the agreement.

Intellectual property is part of the trade agreement

The agreement’s intellectual property chapter establishes commitments concerning several areas of protection, including:

  • Patents;
  • Trademarks;
  • Industrial designs;
  • Copyright;
  • Geographical indications;
  • IP enforcement and rights protection.

Including these areas in a trade agreement reinforces the strategic role of intellectual property in economic relations between Mercosur and EFTA countries.

For companies developing technologies, brands, products or other IP assets, international expansion requires consideration not only of the target market, but also of the rules governing the protection and enforcement of those assets.

63 Brazilian geographical indications to receive protection

One of the agreement’s key provisions is the protection of 63 Brazilian geographical indications in EFTA countries.

Geographical indications link specific products to a particular geographic origin and can represent a relevant asset for industries whose products derive value from their territory of production and associated reputation.

The agreement’s protections provide an additional mechanism for safeguarding these assets in covered markets, particularly for Brazilian products whose geographic origin is part of their commercial differentiation.

Implications for internationally active companies

New trade opportunities also increase the importance of intellectual property planning.

Brazilian companies considering expansion into EFTA markets may need to assess issues such as:

  • trademark protection before international expansion;
  • patent filing strategies in foreign jurisdictions;
  • industrial design protection;
  • identification of intangible assets relevant to internationalization;
  • available mechanisms for enforcing IP rights;
  • differences between Brazilian and foreign IP systems.

In this context, intellectual property becomes more than a legal step taken after a business decision. It becomes part of the planning process for international expansion.

Trade and intellectual property

The inclusion of a dedicated IP chapter illustrates the increasingly close relationship between international trade and intangible asset protection.

As economies become more dependent on technology, brands, knowledge, and innovation, protecting these assets across jurisdictions can become an important component of international business strategy.

The Mercosur-EFTA agreement therefore creates a new environment for Brazilian companies seeking to expand into EFTA markets, particularly those whose competitiveness depends on intellectual property assets.

Implementation will be gradual

The agreement will enter into force gradually for Brazil. According to the Brazilian government, implementation begins with Iceland on October 1, 2026, followed by Norway on November 1, 2026.

This gradual rollout makes it important for companies to monitor the specific rules in each market and the opportunities that arise from the new trade framework.

For businesses planning operations in these countries, the development also highlights the importance of reviewing their intellectual property portfolios and protection strategies in target markets in advance.

IP as part of internationalization strategy

The Mercosur-EFTA agreement illustrates how intellectual property is becoming increasingly integrated into international trade negotiations.

For Brazilian companies, entering new markets involves not only export and business opportunities, but also the need to identify, protect and manage intangible assets across jurisdictions.

Assessing these issues in advance can support a more structured internationalization strategy, particularly in industries where brands, technology, innovation, and product origin represent a significant portion of business value.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.